Vulvovaginal Candidiasis - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 44

Vulvovaginal Candidiasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Vulvovaginal Candidiasis - Pipeline Review, H2 2012', provides an overview of the Vulvovaginal Candidiasis therapeutic pipeline. This report provides information on the therapeutic development for Vulvovaginal Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis. 'Vulvovaginal Candidiasis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vulvovaginal Candidiasis.
- A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vulvovaginal Candidiasis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Vulvovaginal Candidiasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Vulvovaginal Candidiasis Therapeutic Products under Development, Key Players in Vulvovaginal Candidiasis Therapeutics, Vulvovaginal Candidiasis Pipeline Overview, Vulvovaginal Candidiasis Pipeline, Vulvovaginal Candidiasis Pipeline Assessment

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Vulvovaginal Candidiasis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vulvovaginal Candidiasis 7
Vulvovaginal Candidiasis Therapeutics under Development by Companies 9
Vulvovaginal Candidiasis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Vulvovaginal Candidiasis Therapeutics – Products under Development by Companies 15
Vulvovaginal Candidiasis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Vulvovaginal Candidiasis Therapeutics Development 17
Merck & Co., Inc. 17
MethylGene Inc 18
Pevion Biotech Ltd 19
Ferrer Internacional S.A. 20
Vulvovaginal Candidiasis – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Arasertaconazole - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PEV7 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MGCD290 + Fluconazole - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Lavender Vaginal Cream - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Ketoconazole + Clindamycin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Butoconazole Nitrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
r-MP65 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Vulvovaginal Candidiasis Therapeutics – Drug Profile Updates 36
Vulvovaginal Candidiasis Therapeutics – Discontinued Products 38
Vulvovaginal Candidiasis Therapeutics - Dormant Products 39
Vulvovaginal Candidiasis – Product Development Milestones 40
Featured News & Press Releases 40
Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees 40
Oct 11, 2011: Pevion’s Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity 40
Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine 41
Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for Vulvovaginal Candidiasis, H2 2012 7
Products under Development for Vulvovaginal Candidiasis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Merck & Co., Inc., H2 2012 17
MethylGene Inc, H2 2012 18
Pevion Biotech Ltd, H2 2012 19
Ferrer Internacional S.A., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Vulvovaginal Candidiasis Therapeutics – Drug Profile Updates 36
Vulvovaginal Candidiasis Therapeutics – Discontinued Products 38
Vulvovaginal Candidiasis Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for Vulvovaginal Candidiasis, H2 2012 7
Products under Development for Vulvovaginal Candidiasis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Customers who bought this item also bought

• Candidiasis - Pipeline Review, H1 2013
• Mycoses - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Fungal Infections - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Myelodysplastic Syndrome - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012